Victorian-based veterinary products and services provider Apiam Animal Health (AHX) is a stock that taps into two strong tailwinds. The first is Australians’ love of pets. Even before the pandemic, Australians spent $12.2 billion a year on their pets – feeding them, adopting them, and buying them toys, accessories and services – and that amount…
It has been a tough 18 months on the share market for Inghams Group, but things could be starting to turn for Australia and New Zealand’s largest integrated poultry producer. Inghams is one of those classic disappointments for shareholders, in that the stock looked to be going great guns, but hit unexpected turbulence and gave…
The latest buzzword in the renewable energy space is “hydrogen,” with element H – the world’s most abundant – forecast by many to play a major role in the world’s transition to a more sustainable energy future, as an energy carrier that can be produced from a wide range of sources and used in many…
You have to feel for Treasury Wine Estates, Australia’s largest wine company, the maker of well-known brands such as Penfolds and its iconic Grange label, Wynns, Seppelt, Wolf Blass, Pepperjack and Lindeman’s. After starting the year at just over $16, Treasury Wine Estates had moved nicely to $17.70 – then the COVID-19 pandemic stripped its…
Allegra Orthopaedics (AMT, 18.5 cents)Market capitalisation: $19 millionThree-year total return: +7.2% a yearAnalysts’ consensus target price: n/a Since 2014, orthopaedic manufacturer Allegra Orthopaedics has held an exclusive global licence to the composite bio-compatible and bio-degradable ceramic “synthetic bone” material Sr-HT-gahnite, developed at the University of Sydney: the lead product is a 3D-printed spinal cage, which…
Rhinomed (RNO, 17.5 cents)Market capitalisation: $44 millionThree-year total return: +4.1% a yearAnalysts’ consensus valuation: n/a The Melbourne-based Rhinomed is a specialist in respiratory airway technology: it is a world-leading developer of nasal devices made from ultra-soft medical-grade bio-compatible polymers, that helps the volume of air travelling through the nose. The company has brought to market three kinds of…
Company Info: Adherium (ADR, 2.5 cents)Market capitalisation: $17 millionThree-year total return: -33.8% a yearAnalysts’ consensus target price: n/a Adherium is a global leader in medication compliance technology, developing devices that monitor the extent to which patients suffering chronic illness take their medications as prescribed. More than 50% of such patients do not do so, resulting…
One of the stocks most hammered by the COVID correction in February-March was Qantas, which plummeted from $6.67 to $2.14, a fall of 68%, as the effect of the pandemic on air travel began to sink-in to the market. Like most of its peers, Qantas found itself in “the most challenging period in its long…
The forgotten precious metal – silver – is quietly having a blinder of a year. With a 34.7% gain so far, silver is outperforming gold, the S&P 500, the Dow Jones Industrial Average, the DAX Index in Germany, and the Nikkei index in Tokyo. At US$24.27 an ounce, silver is up 63.3% since March, but…
And still they keep coming – here’s the fifth instalment of our series on the fascinating ASX cohort of medical device developers. As always, don’t let the impressive sexiness of the technology persuade you on its own that these stocks are headed for the stars. In each of the three cases presented here, previous investors…
